Meeting
2017 Genitourinary Cancers Symposium
Proton-pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).
Authors
Aly-Khan A. Lalani
Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
Aly-Khan A. Lalani , Rana R. McKay , Xun Lin , Ronit Simantov , Marina D. Kaymakcalan , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 493)
DOI
10.1200/JCO.2017.35.6_suppl.493
Abstract #
493
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.
First Author: Giuseppe Procopio
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2016 Genitourinary Cancers Symposium
Impact of metformin on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.
First Author: Lana Hamieh